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INTRODUCTION
Influenza A virus (IAV), a single-stranded nega-
tive-sense RNA virus, is the most common infec-
tive pathogen in human, causing significant mor-
bidity and mortality in infants and elderly. Severe
influenza causes pneumonia with cardiac compli-
cations, such as myocarditis and acute myocardial
infarction, with a rate of up to 10% (1, 2). In the
process of viral entry into cells, proteolytic process-
ing of a viral envelope fusion protein, heamaggluti-
nin (HA), by host cellular trypsin type proteases is
a prerequisite for membrane fusion activity (3, 4).
IAV infection upregulates cellular ectopic pancreatic
trypsin in various organs and vascular endothelial
cells, which is then secreted into the extracellular
fluid (5, 6). Upregulated trypsin potentiates viral
multiplication by conversion of HA0 into HA1 and
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HA2 and also causes damage through proteinase-
activated receptor-2 (PAR-2) in various tissues (4,
6). Influenza virus infection also evokes innate and
acquired immune responses in host cells via a family
of Toll-like receptors (TLRs), one of the pattern rec-
ognize receptors (PRR), through induction of proin-
flammatory cytokines and interferon (IFN)-β (7-9).
To date, 12 mouse TLRs have been described
(10), and TLR2, TLR3, TLR4, TLR7, TLR8 and TLR9
are the major sensors of viral infection (9). TLR2
and TLR4 detect viral structural proteins, TLR3 rec-
ognizes the viral double-stranded RNA (dsRNA),
TLR7 and TLR8 recognize viral single-stranded RNA
(ssRNA), while TLR9 senses viral double-stranded
DNA (dsDNA) at unmethylated CpG motifs (9).
These TLRs, with the exception of TLR3, transduce
signals through the Myeloid Differentiation factor
88 (MyD88)-dependent pathway. TLR3 uses the
Toll/interleukin-1 receptor (TIR) domain-containing
adaptor inducing interferons (IFNs)-β (TRIF)-de-
pendent pathway (7-9, 11). On the other hand, TLR4
uses both TRIF-dependent and MyD88-dependent
pathways. Following engagement with TLR ligands,
TLR-dependent signals lead to the activation of vari-
ous transcription factors such as interferon regula-
tory factors (IRFs) and nuclear factor-kappaB (NF-
κB) (7). The IRF families are known to induce type
I IFNs, such as IFN-β, and NF-κB is one of the key
transcription factors that regulate various inflamma-
tory mediators (11, 12). In the process of IAV infec-
tion, IAV structural protein is recognized by CD14,
which cooperates with TLR2 and TLR4, for signal
transduction (13). The IAV genome, which con-
sists of ssRNA, is recognized by TLR7/8 (14), while
dsRNA, an intermediate product during viral repli-
cation, is recognized by TLR3 (15).
PAR-2 is a widely expressed tethered ligand re-
ceptor, activated proteolytically by trypsin (16) and
involved in inflammation and immune response by
the release of an array of cytokines and upregula-
tion of proMMP-9 (17-19).
In a recent study, we found that IAV infection in-
duced various cellular factors, such as ectopic pan-
creatic trypsin, matrix metalloproteinases (MMPs),
such as MMP-2 and MMP-9, and proinflammatory
cytokines IL-6, IL-1β and TNF-α, which cross-in-
teract with each other (6) : upregulated trypsin effec-
tively stimulates not only viral multiplication but also
the conversion of proMMP-9 into active MMP-9
(20, 21), active MMP-9 successively converts proin-
flammatory cytokines into their active forms (22,
23) ; active cytokines enhance further production
of MMPs at the transcriptional level (24, 25). Our
study also showed that the above induced-cellular
factors coordinately stimulate viral replication, vas-
cular hyperpermeability and cellular damage. Fur-
thermore, both the inhibition of trypsin activity and
trypsin mRNA knockdown effectively abrogated the
IAV-induced upregulation of all of the aforemen-
tioned cellular factors and protected against heart
dysfunction and cellular damage of cardiomyocytes
(Pan et al ., manuscript submitted for publication).
Although the upregulated pathogenic cellular fac-
tors described above might be downstream events
of the signaling pathways of IAV-TLRs and PAR-2
activation, details of the cross interactions of these
signallings in the IAV-induced pathological changes
in cardiomyocytes and host immune response re-
main to be clarified. In the present study, we ana-
lyzed the effects of selective inhibitors of these sig-
nalings on IAV-induced cellular responses and vi-
ral replication in H9c2 cardiomyocytes.
MATERIAL AND METHODS
Reagents
Dulbecco’s modified Eagle’s medium (DMEM)
was purchased from Invitrogen (Grand Island, NY),
BCATM protein assay kit was obtained from Pierce
(Rockford, IL), 4,6-diamidino-2-phenylindole (DAPI)
from Dojindo (Kumamoto, Japan), enzyme-linked
immunosorbent assay (ELISA) kits form R&D Sys-
tem (Minneapolis, MN), ITS Premix from BD Bi-
osciences (San Jose, CA), RIPA lysis buffer from
Santa Cruz Biotechnology (Santa Cruz, CA), RNeasy
Mini kit from Qiagen (Valencia, CA), SuperScript
III RT from Invitrogen and GeneAmp PCR Re-
agent kit from Applied Biosystems (Bedford, MA).
Specific inhibitors pepinh-TRIF and pepinh-MyD
were from InvivoGen (San Diego, CA), pyrrolidine
dithiocarbamate (PDTC) from Dojindo Laborato-
ries (Kumamoto, Japan), aprotinin from Sigma (St
Louis, MO) and FSLLRY-NH2 (FSY-NH2) from
Bachem (Bubendorf, Switzerland). Antibody against
NF-κB p65 was purchased from Abcam (Cambridge,
MA), antibodies against TLR2, TLR3, TLR4, TLR7,
TLR8, trypsin, MMP-9 and MMP-2 were from Santa
Cruz Biotechnology, antibody against actin from
Chemicon (Temecula, CA) and antibody against IAV
from Takara (Shiga, Japan).
Cell culture and infection
Cardiomyocyte H9c2 cells (ATCC) were cultured
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to sub-confluence in DMEM containing 10% fetal
calf serum, 100 units/ml penicillin/streptomycin and
2 mM L-glutamine. The optimal concentrations of
the specific inhibitors used for experiments were de-
termined by cytotoxicity tests. The cellular toxicity
was analyzed by visual inspection after proliferation
for 24 h with different concentrations of these inhibi-
tors. For infection, cells were washed twice with
calcium- and magnesium-free phosphate-buffered
saline [PBS(-)], then infected with IAV/PR/8/34
(H1N1) at a multiplicity of infection of 1 in serum-
free DMEM supplemented with ITS Premix (infec-
tion medium) for 1 h. Cells were washed twice again
with PBS(-) to remove the unbound viral particles,
followed by incubation for 24 h in fresh infection
medium supplemented with or without the following
inhibitors : 10 μM TRIF inhibitor pepinh-TRIF, 20
μM MyD88 inhibitor pepinh-MyD, 10 μM NF-κB
inhibitor PDTC, 1.5 μM trypsin inhibitor aprotinin
and 40 μM PAR-2 antagonist FSY-NH2. In case of
pepinh-TRIF and pepin-MyD treatments, the cells
were pretreated for 6 h before infection.
Reverse transcription polymerase chain reaction
(RT-PCR)
Total RNA was extracted with RNeasy Mini kit
according to the protocol supplied by the manufac-
turer, and reverse transcribed using universal prim-
ers (Uni 12A : 5’ -AGCAAAAGCAGG-3’, Uni 12G :
5’ -AGCGAAAGCAGG-3’) and SuperScript III RT
for synthesis of IAV cDNA. The following primer
pairs were used to amplify IAV non-structure pro-
tein 1 (NS1) gene segment with GeneAmp PCR
Reagent kit : 5’ -CAGCACTCTTGGTCTGGACAT-3’
(forward) and 5’-CCGATGAGGACTCCAACTGCAT-
3’ (reverse). RT-PCR was initiated at 94for 3 min
followed by 40 cycles of 30-sec denaturation at 94,
30-sec annealing at 60and 30-sec extension at
72. PCR products were analyzed by agarose gel
electrophoresis and visualized by treatment with
ethidium bromide.
Western immunoblotting
Cultured cells were lysed with RIPA lysis buffer.
Extracts were concentrated with Amicon Ultra 10K
device (Millipore, Danvers, MA) by centrifugation
at 4. Protein concentrations of the concentrated
extracts were measured by BCA protein assay kit
and equal amounts (30 μg protein) were loaded onto
SDS-PAGE under reducing condition, as reported
previously (5).
Immunofluorescent staining
Cells were washed briefly with PBS(-), then fixed
in 4% paraformaldehyde for 10 min, followed by
permeabilization with 0.2% Triton X-100 for 5 min.
After blocking with 2% bovine serum albumin for 1
h, cells were incubated with rabbit anti- NF-κB p65
or IAV antibodies overnight at 4, followed by in-
cubation with goat anti-rabbit Texas red-conjugated
secondary antibody (Molecular Probes, Eugene, OR)
at room temperature for 1 h. Nuclei were stained
by 1 μg/ml DAPI for 10 min. Fluorescence labeled
cells were observed under a fluorescence micro-
scope.
ELISA
Culture media was collected and centrifuged at
2000g for 20 min at 4to remove the cell debris.
The levels of IL-6, IL-1β and TNF-α in the culture
media were measured by ELISA kits according to
the respective protocols provided by the manufac-
turer.
Statistical analysis
Results are presented as meanSD. Significance
was calculated by the Student’s t -test and one-way
analysis of variance (ANOVA). A P value less than
0.05 was considered statistically significant.
RESULTS
Changes in TLRs expression levels after IAV infec-
tion
Since TLR2, TLR3, TLR4, TLR7 and TLR8 are the
major sensors of IAV infection, we analyzed the ex-
pression levels of these TLRs in H9c2 cardiomyo-
cytes by western immunoblotting after 24-h mock-
or IAV-infection. IAV infection significantly upregu-
lated the expression of TLR3 and TLR7, markedly
downregulated that of TLR2 and TLR4, and had no
effect on the expression of TLR8 (Fig. 1).
Effects of inhibitors of TLRs, PAR-2 signalings and
trypsin on NF-κB activation by IAV infection in
H9c2 cells
NF-κB is a critical mediator in the downstream of
IAV-induced signaling pathways (26) and its inhibi-
tion effectively suppressed not only IAV replication
but also cellular damage (27-29). In addition, we re-
cently reported that the influenza virus-cytokine- tryp-
sin cycle is one of the key mechanisms of vascular
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hyperpermeability and multiorgan failure in severe
influenza (6). To elucidate the role of TLRs signal-
ing and PAR-2 signaling in the pathological changes
in cardiomyocytes and myocardial immuno response
evoked by IAV infection, we analyzed the effects
of inhibitors of TLRs signaling (including pepinh-
MyD, pepinh-TRIF and the NF-κB inhibitor PDTC,
which block TLR signalings at different steps),
PAR2 antagonist peptide FSY-NH2 and trypsin in-
hibitor aprotinin, on the translocation of the p65
subunit of NF-κB into the cell nucleus, as a marker
of NF-κB activation, by immunofluorescent stain-
ing at 24 h after mock or IAV infection of cardio-
myocytes. The p65 subunit of NF-κB was localized
exclusively in the cytoplasm of uninfected H9c2
cells (mock infection). However, IAV infection re-
sulted in activation of NF-κB and its translocation
from the cytosol to the nucleus. The latter process
was inhibited by PDTC, pepinh-MyD and aprotinin,
but not inhibited clearly by pepin-TRIF and FSY-
NH2 (Fig. 2). These results indicated that NF-κB ac-
tivation by IAV infection is predominant downstream
Fig. 1. Effects of infection of H9c2 cells with IAV on the expression levels of TLRs.
Left : Expression levels of TLR2, TLR3, TLR4, TLR7 and TLR8 were analyzed by western immunoblotting in H9c2 cells at 24 h after
mock and IAV infection. Right : Quantification of the intensity of each band by densitometry. Data represent the expression levels of
TLRs after IAV infection relative to that of mock infection. *P0.05, **P0.01, compared with mock infection.
Fig. 2. Effects of inhibitors of TLRs, PAR-2 signalings and trypsin on activation of NF-kB in H9c2 cells after IAV infection. Intra-
cellular localization of p65 subunit of NF-κB in H9c2 cells was analyzed by immunofluorescent staining at 24 h after mock and IAV
infection, with or without 10 μM pepinh-TRIF, 20 μM pepinh-MyD, 10 μM PDTC, 1.5 μM aprotinin and 40 μM FSY-NH2. Magnifi-
cation,600
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of the MyD88-dependent signaling pathway but
not downstream of the TRIF-dependent signaling
pathway in H9c2 cells. Although trypsin inhibitor
aprotinin also inhibited the translocation of p65
subunit of NF-κB, PAR-2 antagonist FSY-NH2 did
not clearly affect the translocation.
Effects of inhibitors of TLRs, PAR-2 signalings and
trypsin on trypsinogen, proMMP-9, proMMP-2 and
IFN-β expression in H9c2 cells and cytokine levels
in culture media after IAV infection
To investigate the roles of TLRs and PAR-2 sig-
naling pathways in IAV-induced changes in the ex-
pression of cellular factors in cardiomyocytes, the
H9c2 cells were treated with inhibitors of these sig-
naling pathways and trypsin during IAV infection.
Trypsinogen, proMMP-9, proMMP-2 and IFN-β
were all significantly upregulated at 24 h after IAV in-
fection (Fig. 3, A-1 and A-2). Treatment of the cells
with pepinh-MyD, PDTC and aprotinin significantly
inhibited the IAV-induced upregulation of trypsino-
gen, proMMP-9 and proMMP-2, and moderately
inhibited upregulation of IFN-β. The efficiency of
the suppression was similar for pepin-MyD and
PDTC, and both were slightly more potent than
aprotinin. In contrast, FSY-NH2, a PAR-2 recep-
tor antagonist, resulted in slight upregulation of
trypsinogen but had no effects on the other cellu-
lar factors tested. Pepinh-TRIF selectively and sig-
nificantly inhibited IFN-β expression but not the
other factors tested. The levels of proinflammatory
cytokines, such as IL-6, IL-1β and TNF-α, in the
culture media increased significantly after IAV in-
fection for 24 h. Although all inhibitors tested sup-
pressed the upregulation of the tested cytokines,
PDTC, peninh-MyD and aprotinin had the most
potent suppressive efficiencies compared with other
inhibitors (Fig. 3B). These results suggest that
upregulation of trypsinogen, proMMPs and proin-
flammatory cytokines is mediated predominantly
via the MyD88-NF-κB-dependent pathway and also
downstream of the trypsin-mediated viral internali-
zation process.
Fig. 3. Effects of inhibitors of TLRs, PAR-2 signalings and trypsin on the expression of trypsinogen, proMMP-9, proMMP-2 and
IFN-β in H9c2 cells and cytokine levels in culture media after IAV infection. The expression levels of trypsinogen, proMMP-9,
proMMP-2 and IFN-β in H9c2 cells in the absence or presence of 10 μM pepinh-TRIF, 20 μM pepinh-MyD, 10 μM PDTC, 1.5 μM
aprotinin and 40 μM FSY-NH2 were analyzed by RT-PCR at 24 h after mock or IAV infection (A-1). The intensity of each band was
quantified by densitometry. Data represent the expression levels of trypsinogen, proMMP-9 and proMMP-2 in the cell lysates after
IAV infection relative to that of mock infection (A-2). β -Actin as an internal control. *P0.05, **P0.01, versus mock infection. P
0.05, P0.01, versus infection control. B, The concentrations of IL-6, IL-1β and TNF-α in the culture media of cells treated with
inhibitors were analyzed by ELISA after IAV infection for 24 h. Data are meanSD of three independent experiments. *P0.05,
**P0.01, versus mock infection. P0.05, P0.01, versus infection control.
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Effects of inhibitors of TLRs, PAR2 signalings and
trypsin on viral replication
Finally, we analyzed the effects of the same in-
hibitors on viral replication in H9c2 cells. Viral pro-
teins in the infected cardiomyocytes were stained
immunocytochemically. A significant reduction in
the number of infected cells was observed in cells
treated with PDTC and aprotinin, and moderate
reduction with pepinh-MyD, compared with the
infection control. However, the number of infected
cells was slightly but significantly increased when
the cells were treated with pepinh-TRIF and FSY-
NH2 (Fig. 4A). Viral replication monitored by NP
levels in the culture media and analyzed by western
immunoblotting, as well as analysis of NS1 gene by
RT-PCR in the cell lysate showed significant sup-
pression of IAV replication in cells treated with
PDTC and aprotinin, and partly with pepinh-MyD.
In contrast, pepinh-TRIF and FSY-NH2 resulted in
a slight but significant increase in viral replication.
Fig. 4. Effects of inhibitors of TLRs, PAR-2 signalings and trypsin on viral replication. Viral replication in H9c2 cells treated with
or without 10 μM pepinh-TRIF, 20 μM pepinh-MyD, 10 μM PDTC, 1.5 μM aprotinin and 40 μM FSY-NH2 was monitored by im-
munofluorescent staining at 24 h after mock or IAV infection. Viral proteins in the infected cells were visualized by immunofluores-
cence (red). Magnification,200. Nuclei were stained blue by DAPI (A-1). Data represent the percentage of infected cells (A-2).
Viral replication was also monitored by NP levels in culture media by western immunoblotting and NS1 gene in the cell lysate by RT-
PCR under the same experimental conditions as in A (B-1). The intensity of each band was quantified by densitometry. Data repre-
sent the meanSD replication rate based on NP and NS1 values after IAV infection, expressed relative to infection control (B-2).
NS1 levels analyzed by RT-PCR were normalized by β -actin as an internal control. *P0.05, **P0.01, versus mock infection. P
0.05, P0.01, versus infection control.
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DISCUSSION
Severe influenza sometimes causes myocarditis
and acute myocardial infarction, but viral replication
and the pathogenic mechanisms of cardiomyocytes
have not yet been elucidated. In the present study,
we reported upregulation of TLR7 and TLR3 and
downregulation of TLR2 and TLR4 in cardiomyo-
cytes in a manner similar to those found in the lungs
(30, 31) and macrophages (13), respectively. TLR3
and TLR7 are viral nucleic acid sensors that can be
induced by IAV infection (31). In addition, type I
IFNs, which are markedly induced during viral in-
fection, upregulate TLR3 and TLR7 through a posi-
tive feedback (32, 33). This upregulation makes the
cells more sensitive to virus invasion. TLR2 and
TLR4 are not the PRRs for IAV. They mediate sig-
nal transduction with CD14 by recognition of the
IAV surface antigen (13). Downregulation of TLR2
and TLR4 might be the result of virus-induced shut-
down of the host protein synthesis machinery.
In the pathogenesis of IAV infection, various cel-
lular factors, such as ectopic pancreatic trypsin,
MMPs and cytokines, are induced and secreted into
the extracellular milieu after infection. These factors
in turn enhance the pathogenesis via their receptors
and signal transductions in cooperation with TLRs’
signallings. MyD88 is an adaptor molecule for TLR2,
TLR4, TLR7 and TLR8, and pepinh-MyD is a pep-
tide that blocks MyD88 signaling by inhibiting its
homodimerization through binding. Pepinh-TRIF is
a peptide that blocks TRIF signaling by interfering
with TLR-TRIF interaction. NF-κB is a crucial tran-
scription factor for IAV replication and inflammatory
responses, and PDTC is a potent inhibitor of NF-κB,
based on its oxygen radical-scavenging properties
(34) or oxidation of critical thiols in NF-κB (35).
Proteolytic activation of HA by trypsin is a step that
precedes membrane fusion with viral internalization
(36, 37) and the binding of viral ssRNA to TLR7/8.
Trypsin also proteolytically activates the conversion
of proMMP-9 to actMMP-9 and inactive PAR-2 to
active PAR-2. Aprotinin is a non-permeable trypsin-
type protease inhibitor with a molecular mass of
6,512 and FSY-NH2 peptide is an antagonist of PAR-
2. Among these inhibitors tested, aprotinin and
pepinh-MyD or PDTC, which inhibit trypsin-de-
pendent viral internalization and TLR7/8-MyD88-
NF-κB signalling, respectively, preferentially inhib-
ited viral replication and upregulation of trypsinogen
and proMMPs (Figs. 3 and 4).
The potent antiviral cytokines type I IFNs, do not
only inhibit viral replication directly but also induce
the expression of various antiviral proteins, such
as myxovirus-resistance protein GTPase, ribonu-
clease L, RNA-dependent protein kinase R, 2’,5’ -
oligoadenylate synthetase and RNA-specific adeno-
sine deaminase, in neighboring cells (11). Pepinh-
TRIF selectively and significantly suppressed the
production of IFN-β through IRF and also moder-
ately inhibited the production of proinflammatory
cytokines (Fig. 3). These results indicate that IAV
infection stimulates diverse signaling pathways, one
for stimulation of viral replication and upregulation
of proinflammatory cytokines, trypsinogen and
proMMPs through TLR7/8-MyD88-NF-κB signal-
ing, and the other for stimulation of IFN-β produc-
tion as a cellular immune response through TLR3-
TRIF-IRF signaling. The inhibitory effect of pepinh-
MyD on viral replication was slightly less than those
of PDTC and aprotinin, probably because the inhibi-
tor also suppressed the TLR7/8-MyD88-IRF sig-
naling for IFN-β production, although MyD88-IRF
signaling is not the major pathway for induction of
IFNs.
PAR-2 mediates the classical signal of inflamma-
tion, and its inhibition reveals anti-inflammatory ef-
fect (38-40). In addition, PAR-2 is considered to act
as the “sensory” arm of a negative feedback mecha-
nism to downregulate trypsin expression (41). Upon
activation, PAR-2 is internalized and forms a com-
plex with β -arrestin and extracellular signal regu-
latory kinase (ERK)1/2. This complex prevents
ERK1/2 translocation into the nucleus, thereby ef-
fectively preventing trypsinogen transcription (42,
43). In the present study, we found that the inhibi-
tory effects of PAR-2 antagonist FSY-NH2 (44) on
the secretion of proinflammatory cytokines IL-6,
IL-1β and TNF-α was moderate in H9c2 cells, in
comparison with its inhibitory effects on human um-
bilical vein endothelial cells reported previously (17).
In addition, FSY-NH2 mildly upregulated trypsino-
gen and viral replication, probably because inhibi-
tion of PAR-2 activation by FSY-NH2 may abrogate
the negative feedback mechanism in cardiomyo-
cytes.
In conclusion, the present study indicates that
TLR7/8-MyD88, TLR3-TRIF, and PAR-2 signaling
pathways mediate distinct cellular responses in
cardiomyocytes after IAV infection (Fig. 5). Inhibi-
tors, such as aprotinin for trypsin, pepinh-MyD for
TLR7/8-MyD88 signaling and PDTC for NF-κB
activation, significantly suppressed viral replication
and upregulation of proinflammatory cytokines,
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proMMPs and trypsinogen. These results suggest
that combination treatment with inhibitors of
MyD88-NF-κB signaling and trypsin is potentially
useful for IAV-induced myocarditis. In addition, the
TLR3-TRIF-IRF signaling pathway seems important
in the induction of antiviral cellular factor IFN-β in
cardiomyocytes. Although PAR-2 antagonist FSY-
NH2 mildly inhibited proinflammatory cytokine pro-
duction, it slightly upregulated IAV replication.
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